Evekeo

SKIP-FOR-NOW for Dylan — same family rationale as Adderall, refer to that file as parent analysis. Evekeo is pure 50:50 racemic amphetamine sulfate IR, the modern rebrand of 1937 Benzedrine. Compared to Adderall's 75:25 d/l ratio, Evekeo has proportionally more l-amphetamine → marginally less euphoric/CNS pull, marginally more peripheral noradrenergic load (HR/BP/peripheral vasoconstriction). For a 20yo combat athlete already running daily cardio load, that l-amph excess is the wrong direction. Brand-only US pricing (~$400/mo, no generic) and ongoing 2024-2026 amphetamine shortage seal the practical case.

Evekeo is single-entity racemic amphetamine sulfate — pure 50% d-amphetamine + 50% l-amphetamine in a single salt (amphetamine sulfate), not the four-salt blend Adderall uses. The releaser mechanism is identical to Adderall (substrate uptake → TAAR1 agonism → DAT/NET reverse transport + VMAT2 disruption + weak MAO-A inhibition — see parent Adderall file for the four-step mechanism breakdown). The functional difference is the isomer ratio:

Adderall = 75% d-amphetamine + 25% l-amphetamine (3:1 d-skewed) Evekeo = 50% d-amphetamine + 50% l-amphetamine (1:1 racemic) Dexedrine = 100% d-amphetamine (pure d)

What the ratio shift means functionally:

• d-amphetamine (50% of Evekeo): Stronger CNS effects per mg — striatal DA release, euphoria, cognitive "amped" feel, drive. Half-life ~10 hr.
• l-amphetamine (50% of Evekeo): Weaker CNS profile per mg, but disproportionately stronger peripheral cardiovascular and norepinephrine effects — more BP elevation, more HR, more peripheral vasoconstriction, more "wired-edgy" feel without proportional cognitive lift. Half-life ~13 hr.

Practical translation:

• Per equivalent CNS effect, Evekeo delivers more peripheral NE load than Adderall, and substantially more than Dexedrine.
• The marketed framing (Arbor Pharmaceuticals 2014 relaunch) is "better balance for ADHD with co-morbid hyperactivity/impulsivity" — i.e., the noradrenergic arm of attention regulation. Some clinicians choose Evekeo over Adderall when they want stronger peripheral NE for behavioral activation/impulsivity reduction without proportionally raising the dopaminergic euphoria signal (lower theoretical abuse liability per mg of behavioral effect).
• For a healthy-adult cognitive enhancement use case, the higher l-amph ratio is a net negative — more cardiac load, less "cognitive amped" feel per mg, and the Roberts 2020 meta-analysis null finding for d-amphetamine in healthy adults applies a fortiori to Evekeo (lower CNS-active fraction).

Practical equivalence: ~10mg Evekeo ≈ 8mg Adderall IR (Evekeo is ~80% as potent on CNS measures, mg-for-mg, due to the lower d-amphetamine fraction). Dosed similarly in the IR window (4-6 hr clinical effect).